CNO Financial Group, Inc. (CNO)
Live price chart, market sentiment, and community perspectives for CNO Financial Group, Inc. (NYSE: CNO).
Live price chart, market sentiment, and community perspectives for CNO Financial Group, Inc. (NYSE: CNO).
On our desk, we are tracking the massive 45% surge in operating EPS to $1.33 for Q2 2026. Management raised full-year guidance to a range of $4.60–$4.80. However, with the stock trading at an 18.4x GAAP P/E and 1.9x P/B—both sitting above historical norms—our sentiment is that a lot of good news is already priced in. We need to see sustained double-digit growth to justify further multiple expansion.
In assessing their financial reporting protocols, the beat on Zacks consensus estimates by 27.3% for Q2 adjusted EPS ($1.26 vs expectations) underscores disciplined underwriting and favorable portfolio book yields. The expansion in alternative investment income and general account growth also provided a strong cushion, validating their asset-liability management in the current interest rate environment.
From a risk management standpoint, the structural tailwind from consumer preferences shifting away from Medicare Advantage toward Medicare Supplement products is a massive positive. This has helped CNO secure its 16th consecutive quarter of new annualized premium growth. That kind of longevity in a sales streak highlights a durable moat in their captive agent model, but watch out for increasing TechMod tech costs cutting into operational leverage.
Reviewing the capital return profile, the execution of $60 million in share repurchases during Q2 underpins management's confidence in their robust free cash flow generation. With an operating ROE of 13.1% (excluding significant items) and a book value per share excluding AOCI at $39.92, the balance sheet remains sound, though we are keeping an eye on broader macro volatility impacting investment portfolios.
Watching the 50-day MA and valuation metrics on our desk, CNO's forward 12-month P/E of 11.15x compared to the industry average of 9.35x signals that the market is beginning to accord them a quality premium. Whether this valuation looks 'full' depends heavily on whether they can beat the upper bound of their newly raised EPS guidance by year-end.
Explore plasma cleansing, somatic organ swaps, and BCI.